Cystic Fibrosis: New Compounds Display Strong Therapeutic Potential
Cystic fibrosis is a genetic disorder that affects the epithelia2 of numerous organs, and particularly those in the lungs, pancreas and intestine. In the lungs, this takes the form of insufficient epithelial hydration, resulting in excess mucus in the bronchi. This mucus retains pathogenic agents and favors the onset of chronic infections and inflammatory conditions that are ultimately fatal to the sufferer.
The disease is caused by mutations in the gene coding for a protein called CFTR (cystic fibrosis transmembrane conductance regulator). This protein, which is essential to ensure the passage of water through an epithelium, is an ion channel that allows chloride ions to pass through cell membranes. To date, about 2,000 gene mutations that cause the disease have been determined, but 70% of cases of cystic fibrosis are due to a single mutation called ΔF508. And it is this mutation that is targeted by the recently-discovered compounds.
The scientists used computer techniques to screen 200,000 compounds, looking for those that might interact with a specific zone in the abnormal protein, and found about a dozen potentially active molecules. Using these 12 compounds, they then performed in-vitro tests on human cell cultures and in-vivo experiments on mice showing this mutation. They were thus able to observe that two of these compounds allowed the mutated ΔF508-CFTR protein to be trafficked to the membrane and fulfill its role.
One of the highlights of this work was that the scientists were able to describe the mechanism of action of these two compounds. In itself, and despite its mutation, the ΔF508-CFTR protein may satisfactorily fulfill its function. The problem is that once it is synthesized, it is recognized as being abnormal by keratin 8, another protein which favors its degradation, thus preventing ΔF508-CFTR from reaching the cell membrane. The compounds discovered by the scientists inhibit the interaction between keratin 8 and ΔF508-CFTR so that the protein can be deployed appropriately and fulfill its role as an ion channel. The scientists think that for potential therapeutic purposes, the two molecules they have discovered could be associated with "potentiating" compounds that would enhance the activity of ΔF508-CFTR.
The scientists now want to determine whether these two compounds do indeed cause a reduction in the susceptibility to infection of cystic fibrosis mice models. They also hope to start clinical trials in cystic fibrosis patients in the coming years.
This research is supported through various contracts, notably European3, and by the charitable organizations "Vaincre la Mucoviscidose", "Mucoviscidose: ABCF" and "Mucovie".
Source: CNRS (Délégation Paris Michel-Ange) via AlphaGalileo
- Research carried out by scientists at the Centre de Recherche Croissance et Signalisation; Canalopathies Epithéliales team working on cystic fibrosis and other diseases, at the Institut Fédératif de Recherche Necker-Enfants Malades (CNRS/Inserm/Université Paris Descartes), in collaboration with scientists from the Institut de Physiologie et Biologie Cellulaires (CNRS/Université de Poitiers); the Department of Bioinformatics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, (Warszawa, Poland); the Department of Molecular Genetics, German Cancer Research Center, (Heidelberg, Germany); the Laboratory of Plant Molecular Biology, Faculty of Biology, Warsaw University (Warszawa, Poland); the Department of Physiology, McGill University (Montreal, Canada), and Epithelix (Geneva, Switzerland).
- The epithelium is a continuum of connected cells (tissue) that constitutes the boundary between the inside and outside of the body.
- FP6 European contracts: NEUPROCF; ANR contracts: EICO-CF and CORCF (as from 2014); Legs Poix-Université Paris Descartes.
Published on : Mon, 30 Sep 2013
Print as PDF
17 critical parameters from a blood sample as small as 45 µL Not available in the US When the sample is small but your diagnostic needs are big, the ABL90 FLEX PLUS blood gas analyzer provides critical insights with a turnaround time of less than...
NovaPort cannulas: The safe access to the vascular system. NovaPort® twin double lumen cannulas are specifically developed for veno-venous vascular access. NovaPort one single lumen cannulas are specifically developed for the percutaneous connection (KU)...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...